Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02873936 · ClinicalTrials.gov registry record · Phase 3
Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 449
- Enrollment target
NCT02873936 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 449 participants.
The verdict
NCT02873936, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 449 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the effects of filgotinib versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA) as measured by the percentage of participants achieving an American College of Rheumatology 20% improvement response (ACR20) at Week 12.
Interventions
- DRUG Filgotinib
- DRUG Placebo to match filgotinib
- DRUG csDMARDs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 449 participants |
| Start Date | 2016-07-27 |
| Est. Completion | 2018-06-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02873936
The ClinicalTrials.gov registry entry for NCT02873936 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 449 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Filgotinib is the first listed.
NCT02873936 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02873936 about?
NCT02873936 is a clinical study titled "Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment". The primary objective of this study is to evaluate the effects of filgotinib versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA) as measured by the percentage of participants achieving an American College of Rheumatology 20% improvement response (ACR20) at Week 12.
What is the current status of trial NCT02873936?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 449 participants. The study started on 2016-07-27. Estimated completion is 2018-06-26.
What interventions are being tested in trial NCT02873936?
The interventions under investigation include: Filgotinib (DRUG), Placebo to match filgotinib (DRUG), csDMARDs (DRUG).
Who is sponsoring clinical trial NCT02873936?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.